Screener
Castle Biosciences CSTL Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Long-term debt | 8,399 | 9,640 |
| Noncurrent portion of contingent consideration | 1,500 | 1,500 |
| Noncurrent operating lease liabilities | 25,116 | 25,217 |
| Noncurrent finance lease liabilities | 288 | 314 |
| Deferred tax liability | 2,325 | 2,335 |
| Total liabilities | 86,389 | 107,683 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders’ Equity |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's finance lease liabilities?
- Castle Biosciences (CSTL) reported finance lease liabilities of $288K in Q1 2026.
- How has Castle Biosciences's finance lease liabilities changed year-over-year?
- Castle Biosciences's finance lease liabilities decreased by 12.2% year-over-year, from $328K to $288K.
- What is the long-term trend for Castle Biosciences's finance lease liabilities?
- Over 4 years (2021 to 2025), Castle Biosciences's finance lease liabilities has grown at a 26.1% compound annual growth rate (CAGR), from $124K to $314K.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.
Ask your AI about Castle Biosciences's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude